AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus
The investment, its largest since its inception, demonstrates continued progress against AbbVie's $100 billion commitment to US research and development (R&D) and capital investments, including manufacturing, over the next decade.
AbbVie announced a $1.4 billion investment to build a 185-acre pharmaceutical manufacturing campus in Durham, North Carolina. The state-of-the-art campus (will integrate advanced manufacturing and laboratory technologies with artificial intelligence (AI) to support the production of AbbVie's immunology, neuroscience and oncology medicines.
This is AbbVie's first major investment in North Carolina. The AbbVie Durham campus, located near Research Triangle Park, was selected for the strength of the region's local workforce and its ability to support future expansion. Construction will begin this year, with completion expected by the end of 2028.
"Our investment in North Carolina represents a significant milestone for AbbVie as our largest capital investment to date and an important expansion of our manufacturing footprint into a new region of the United States," said Robert A. Michael, Chairman and CEO, AbbVie. "By establishing this campus, we are strengthening our ability to support future medical breakthroughs while also creating new jobs and a long-term partnership with Durham and the State of North Carolina."
Over the next four years, AbbVie plans to hire 734 people, including engineers, scientists, manufacturing operators, and laboratory technicians. The project will also support the local economy by generating more than 2,000 construction jobs during campus development.
This project is part of the Company's $100 billion commitment to US R&D and capital investments, including manufacturing, over the next decade. The first phase of construction will include small volume parenteral (SVP) drug product manufacturing facilities, next-generation laboratories, a warehouse, administrative offices, and employee wellness facilities with room to support AbbVie's growing pipeline.
Small volume parenterals are sterile injectable pharmaceutical products with volumes typically less than 100 mL, including vials, prefilled cartridges, and prefilled syringes containing medicines for injection or infusion. When completed, this campus will serve as AbbVie's US center of excellence for SVP manufacturing and deliver next-generation medicines to patients in the US and worldwide.
